Humanigen, Inc. (HGENQ)
- Previous Close
0.0002 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.2070 - Volume
505 - Avg. Volume
17,646 - Market Cap (intraday)
119 - Beta (5Y Monthly) -1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 21, 2024 - May 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
www.humanigen.comRecent News: HGENQ
Performance Overview: HGENQ
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HGENQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HGENQ
Valuation Measures
Market Cap
23.82k
Enterprise Value
-21.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.01
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-85.05%
Return on Equity (ttm)
--
Revenue (ttm)
1.7M
Net Income Avi to Common (ttm)
-53.63M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
3.1M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-45.92M
Research Analysis: HGENQ
Company Insights: HGENQ
HGENQ does not have Company Insights